William Blair Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)

William Blair assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI - Free Report) in a report published on Friday, Marketbeat reports. The firm issued an outperform rating on the stock.

Other equities analysts also recently issued research reports about the company. Jefferies Financial Group increased their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Raymond James reiterated a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. cut their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, October 11th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Finally, Cantor Fitzgerald cut shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, October 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Denali Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.40.

Denali Therapeutics Stock Up 2.0 %

Shares of NASDAQ:DNLI traded up $0.42 during trading on Friday, hitting $21.26. 642,314 shares of the stock traded hands, compared to its average volume of 670,407. The company has a fifty day moving average price of $24.62 and a two-hundred day moving average price of $24.85. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same quarter in the prior year, the firm earned ($0.72) EPS. On average, equities research analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the company's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at $6,529,495.83. This represents a 14.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,658 shares of company stock worth $1,667,943. Insiders own 7.90% of the company's stock.

Institutional Trading of Denali Therapeutics

Several hedge funds have recently made changes to their positions in the company. FMR LLC grew its holdings in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock worth $109,223,000 after buying an additional 1,451,770 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Denali Therapeutics during the second quarter valued at about $24,454,000. Wellington Management Group LLP raised its stake in shares of Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock valued at $312,491,000 after acquiring an additional 903,683 shares during the period. Finally, Integral Health Asset Management LLC acquired a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $7,546,000. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.